Skip to main content
SpringerLink
Log in

Hybrid Imaging of the Head and Neck Region

  • Chapter
  • First Online:
Nuclear Medicine Textbook

  • 2467 Accesses

Abstract

The term head and neck cancer (HNC) generally encompasses malignant neoplasms of soft tissue origin of the oral cavity, lips, nasal cavity, paranasal sinuses, pharynx, larynx and salivary glands, as well as sarcomas arising in this region. The skin is sometimes included as well. About 95% are squamous cell carcinomas (or variants) arising from the mucosa or adenocarcinomas from the associated secretory glands [1]. The major risk factors for squamous cell carcinoma of the head and neck (HNSCC) are a history of tobacco and alcohol use; risk is increased when either of these factors is present individually, but that risk is multiplied when both factors are present in combination [2]. Over the past decade, the importance of infection by the human papillomavirus (HPV) in the pathogenesis of oropharyngeal cancers has been recognized [3], and Epstein-Barr virus has emerged as an important predisposing condition for the development of non-keratinizing squamous cell carcinoma of the nasopharynx [4].

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
Chapter
USD 29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD 149.00
Price excludes VAT (USA)
  • Available as EPUB and PDF
  • Read on any device
  • Instant download
  • Own it forever
Hardcover Book
USD 199.99
Price excludes VAT (USA)
  • Durable hardcover edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

References

  1. Escott EJ. Role of positron emission tomography/computed tomography (PET/CT) in head and neck cancer. Radiol Clin North Am. 2013;51:881–93.

    PubMed  Google Scholar 

  2. Blot WJ, McLaughlin JK, Winn DM, Austin DF, Greenberg RS, Preston-Martin S, et al. Smoking and drinking in relation to oral and pharyngeal cancer. Cancer Res. 1988;48:3282–7.

    CAS  PubMed  Google Scholar 

  3. Winquist E, Agbassi C, Meyers BM, Yoo J, Chan KKW. Head and Neck Disease Site Group. Systemic therapy in the curative treatment of head and neck squamous cell cancer: a systematic review. J Otolaryngol Head Neck Surg. 2017;46(1):29. https://doi.org/10.1186/s40463-017-0199-x.

    Article  PubMed  PubMed Central  Google Scholar 

  4. Hettmann A, Demcsák A, Decsi G, Bach Á, Pálinkó D, Rovó L, et al. Infectious agents associated with head and neck carcinomas. Adv Exp Med Biol. 2016;897:63–80.

    PubMed  Google Scholar 

  5. Cammaroto G, Quartuccio N, Sindoni A, Di Mauro F, Caobelli F, Young AIMN Working Group. The role of PET/CT in the management of patients affected by head and neck tumors: a review of the literature. Eur Arch Otorhinolaryngol. 2016;273:1961–73.

    PubMed  Google Scholar 

  6. Oyen WJG, Marres HAM, Kaanders JHAM. Progress in nuclear medicine procedures in head and neck oncology. Q J Nucl Med Mol Imaging. 2011;55:485–6.

    CAS  PubMed  Google Scholar 

  7. Amin MB, Greene FL, Edge SB, Compton CC, Gershenwald JE, Brookland RK, et al. The Eighth Edition AJCC Cancer Staging Manual: continuing to build a bridge from a population-based to a more “personalized” approach to cancer staging. CA Cancer J Clin. 2017;67:93–9.

    PubMed  Google Scholar 

  8. Lydiatt WM, Patel SG, O’Sullivan B, Brandwein MS, Ridge JA, Migliacci JC, et al. Head and neck cancers-major changes in the American Joint Committee on Cancer eighth edition cancer staging manual. CA Cancer J Clin. 2017;67:122–37.

    PubMed  Google Scholar 

  9. Al-Ibraheem A, Buck A, Krause BJ, Scheidhauer K, Schwaiger M. Clinical applications of FDG PET and PET/CT in head and neck cancer. J Oncol. 2009;2009:1–13.

    Google Scholar 

  10. Yongkui L, Jian L, Wanghan, Jingui L. 18FDG-PET/CT for the detection of regional nodal metastasis in patients with primary head and neck cancer before treatment: a meta-analysis. Surg Oncol. 2013;22:e11–6.

    PubMed  Google Scholar 

  11. Kyzas PA, Evangelou E, Denaxa-Kyza D, Ioannidis JPA. 18F-fluorodeoxyglucose positron emission tomography to evaluate cervical node metastases in patients with head and neck squamous cell carcinoma: a meta-analysis. J Natl Cancer Inst. 2008;100:712–20.

    PubMed  Google Scholar 

  12. Yoo J, Henderson S, Walker-Dilks C. Evidence-based guideline recommendations on the use of positron emission tomography imaging in head and neck cancer. Clin Oncol. 2013;25:e33–66.

    CAS  Google Scholar 

  13. Lonneux M, Hamoir M, Reychler H, Maingon P, Duvillard C, Calais G, et al. Positron emission tomography with [18F]Fluorodeoxyglucose improves staging and patient management in patients with head and neck squamous cell carcinoma: a multicenter prospective study. J Clin Oncol. 2010;28:1190–5.

    CAS  PubMed  Google Scholar 

  14. Adelstein D, Gillison ML, Pfister DG, Spencer S, Adkins D, Brizel DM, et al. NCCN guidelines insights: head and neck cancers, version 2.2017. J Natl Compr Cancer Netw. 2017;15:761–70.

    CAS  Google Scholar 

  15. Ciernik IF, Dizendorf E, Baumert BG, Reiner B, Burger C, Davis JB, et al. Radiation treatment planning with an integrated positron emission and computer tomography (PET/CT): a feasibility study. Int J Radiat Oncol Biol Phys. 2003;57:853–63.

    PubMed  Google Scholar 

  16. Moule RN, Kayani I, Moinuddin SA, Meer K, Lemon C, Goodchild K, et al. The potential advantages of 18FDG PET/CT-based target volume delineation in radiotherapy planning of head and neck cancer. Radiother Oncol. 2010;97:189–93.

    PubMed  Google Scholar 

  17. Daisne J-F, Duprez T, Weynand B, Lonneux M, Hamoir M, Reychler H, et al. Tumor volume in pharyngolaryngeal squamous cell carcinoma: comparison at CT, MR imaging, and FDG PET and validation with surgical specimen. Radiology. 2004;233:93–100.

    PubMed  Google Scholar 

  18. Koshy M, Paulino AC, Howell R, Schuster D, Halkar R, Davis LW. F-18 FDG PET-CT fusion in radiotherapy treatment planning for head and neck cancer. Head Neck. 2005;27:494–502.

    PubMed  Google Scholar 

  19. Dietl B, Marienhagen J, Kühnel T, Schreyer A, Kölbl O. The impact of FDG-PET/CT on the management of head and neck tumours: the radiotherapist’s perspective. Oral Oncol. 2008;44:504–8.

    CAS  PubMed  Google Scholar 

  20. Abramyuk A, Appold S, Zöphel K, Baumann M, Abolmaali N. Modification of staging and treatment of head and neck cancer by FDG-PET/CT prior to radiotherapy. Strahlenther Onkol. 2013;189:197–201.

    CAS  PubMed  Google Scholar 

  21. Mak D, Corry J, Lau E, Rischin D, Hicks RJ. Role of FDG-PET/CT in staging and follow-up of head and neck squamous cell carcinoma. Q J Nucl Med Mol Imaging. 2011;55:487–99.

    CAS  PubMed  Google Scholar 

  22. Isles MG, McConkey C, Mehanna HM. A systematic review and meta-analysis of the role of positron emission tomography in the follow up of head and neck squamous cell carcinoma following radiotherapy or chemoradiotherapy. Clin Otolaryngol. 2008;33:210–22.

    CAS  PubMed  Google Scholar 

  23. Cheung PKF, Chin RY, Eslick GD. Detecting residual/recurrent head neck squamous cell carcinomas using PET or PET/CT. Otolaryngol Neck Surg. 2016;154:421–32.

    Google Scholar 

  24. Moeller BJ, Rana V, Cannon BA, Williams MD, Sturgis EM, Ginsberg LE, et al. Prospective risk-adjusted [18F]Fluorodeoxyglucose positron emission tomography and computed tomography assessment of radiation response in head and neck cancer. J Clin Oncol. 2009;27:2509–15.

    PubMed  PubMed Central  Google Scholar 

  25. Lee JC, Kim JS, Lee JH, Nam SY, Choi S-H, Lee S-W, et al. F-18 FDG-PET as a routine surveillance tool for the detection of recurrent head and neck squamous cell carcinoma. Oral Oncol. 2007;43:686–92.

    CAS  PubMed  Google Scholar 

  26. Issing WJ, Taleban B, Tauber S. Diagnosis and management of carcinoma of unknown primary in the head and neck. Eur Arch Otorhinolaryngol. 2003;260:436–43.

    PubMed  Google Scholar 

  27. Lee JR, Kim JS, Roh J-L, Lee JH, Baek JH, Cho K-J, et al. Detection of occult primary tumors in patients with cervical metastases of unknown primary tumors: comparison of 18F-FDG PET/CT with contrast-enhanced CT or CT/MR imaging — prospective study. Radiology. 2015;274:764–71.

    PubMed  Google Scholar 

  28. Boellaard R, Delgado-Bolton R, Oyen WJG, Giammarile F, Tatsch K, Eschner W, et al. FDG PET/CT: EANM procedure guidelines for tumour imaging: version 2.0. Eur J Nucl Med Mol Imaging. 2015;42:328–54.

    CAS  PubMed  Google Scholar 

  29. Zanotti-Fregonara P, Laforest R, Wallis JW. Fetal radiation dose from 18F-FDG in pregnant patients imaged with PET, PET/CT, and PET/MR. J Nucl Med. 2015;56:1218–22.

    CAS  PubMed  Google Scholar 

  30. Delbeke D, Coleman RE, Guiberteau MJ, Brown ML, Royal HD, Siegel BA, et al. Procedure guideline for tumor imaging with 18F-FDG PET/CT 1.0. J Nucl Med. 2006;47:885–95.

    PubMed  Google Scholar 

  31. Wong TZ, Fras IM. PET/CT protocols and practical issues for the evaluation of patients with head and neck cancer. PET Clin. 2007;2:413–21.

    PubMed  Google Scholar 

  32. The Medical Electrical Safety Standards, IEC 60601-1/EN 60601-1.

    Google Scholar 

  33. The Medical ECM Standards, IEC 60601-1-2, EN 60601-1-2.

    Google Scholar 

  34. Quantitative Imaging Biomarkers Alliance. Quantitative FDG-PET Technical Committee. UPICT oncology FDG-PET CT protocol. http://qibawiki.rsna.org/index.php?title=FDG-PET_tech_ctte. Accessed 23 Nov 2014.

  35. ACR Guidelines and Standards Committee. ACR-SPR practice parameter for performing FDG-PET/CT in oncology. American College of Radiology. 2014. http://www.acr.org/~/media/71B746780F934F6D8A1BA5CCA5167EDB.pdf. Accessed 23 Nov 2014.

  36. Cook GJ, Fogelman I, Maisey MN. Normal physiological and benign pathological variants of 18-fluoro-2-deoxyglucose positron-emission tomography scanning: potential for error in interpretation. Semin Nucl Med. 1996;26:308–14.

    CAS  PubMed  Google Scholar 

  37. Quantitative Imaging Biomarkers Alliance. FDG-PET/CT Technical Committee. FDG-PET/CT as an imaging biomarker measuring response to cancer therapy, version 1.05, Publicly Reviewed Version. Quantitative Imaging Biomarkers Alliance. 2013. http://www.rsna.org/uploadedfiles/rsna/content/science_and_education/qiba/qiba_fdg-pet_profile_v105_publicly_reviewed_version_final_11dec2013.pdf. Accessed 23 Nov 2014.

  38. Wahl RL, Jacene H, Kasamon Y, Lodge MA. From RECIST to PERCIST: evolving considerations for PET response criteria in solid tumors. J Nucl Med. 2009;50(Suppl 1):122S–50.

    CAS  PubMed  Google Scholar 

  39. Boellaard R, O’Doherty MJ, Weber WA, et al. FDG PET and PET/CT: EANM procedure guidelines for tumour PET imaging: version 1.0. Eur J Nucl Med Mol Imaging. 2010;37:181–200.

    PubMed  Google Scholar 

  40. Andrade RS, Heron DE, Degirmenci B, et al. Posttreatment assessment of response using FDG-PET/CT for patients treated with definitive radiation therapy for head and neck cancers. Int J Radiat Oncol Biol Phys. 2006;65:1315–22.

    PubMed  Google Scholar 

  41. Kawabe J, Higashiyama S, Yoshida A, Kotani K, Shiomi S. The role of FDG PET-CT in the therapeutic evaluation for HNSCC patients. Jpn J Radiol. 2012;30:463–70.

    CAS  PubMed  Google Scholar 

  42. Niederkohr RD, Greenspan BS, Prior JO, et al. Reporting guidance for oncologic 18F-FDG PET/CT imaging. J Nucl Med. 2013;54:756–61.

    CAS  PubMed  Google Scholar 

  43. Rischin D, Hicks RJ, Fisher R, et al. Prognostic significance of [18F]-misonidazole positron emission tomography-detected tumor hypoxia in patients with advanced head and neck cancer randomly assigned to chemoradiation with or without tirapazamine: a substudy of Trans-Tasman Radiation Oncology Group Study 98.02. J Clin Oncol. 2006;24:2098–104.

    PubMed  Google Scholar 

  44. Troost EGC, Schinagl DAX, Bussink J, Boerman OC, van der Kogel AJ, Oyen WJG, Kaanders JHAM. Innovations in radiotherapy planning of head and neck cancers: role of PET. J Nucl Med. 2010;51:66–76.

    PubMed  Google Scholar 

  45. Lehtiö K, Oikonen V, Grönroos T, Eskola O, Kalliokoski K, Bergman J, et al. Imaging of blood flow and hypoxia in head and neck cancer: initial evaluation with [15O]H2O and [18F]fluoroerythronitroimidazole PET. J Nucl Med. 2001;42:1643–52.

    PubMed  Google Scholar 

  46. van Dijk LK, Boerman OC, Kaanders JH, Bussink J. PET imaging in head and neck cancer patients to monitor treatment response: a future role for EGFR-targeted imaging. Eur J Nucl Med Mol Imaging. 2017;44(Suppl 1):4–16.

    Google Scholar 

  47. Havekes B, King K, Lai EW, Romijn JA, Corssmit EP, Pacak K. New imaging approaches to phaeochromocytomas and paragangliomas. Clin Endocrinol. 2010;72:137–45.

    CAS  Google Scholar 

  48. Guichard JP, Fakhry N, Franc J, Herman P, Righini CA, Taieb D. Morphological and functional imaging of neck paragangliomas. Eur Ann Otorhinolaryngol Head Neck Dis. 2017;134:243–8.

    PubMed  Google Scholar 

  49. Judenhofer MS, Wehrl HF, Newport DF, et al. Simultaneous PET-MRI: a new approach for functional and morphological imaging. Nat Med. 2008;14:459–65.

    CAS  PubMed  Google Scholar 

  50. Platzek I. 18F-Fluorodeoxyglucose PET/MR imaging in head and neck cancer. PET Clin. 2016;11:375–86.

    PubMed  Google Scholar 

  51. van der Vos CS, Koopman D, Rijnsdorp S, Arends AJ, Boellaard R, van Dalen JA, et al. Quantification, improvement, and harmonization of small lesion detection with state-of-the-art PET. Eur J Nucl Med Mol Imaging. 2017;44(Suppl 1):4–16.

    PubMed  PubMed Central  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Nuclear Medicine Department, Hospital de la Santa Creu i Sant Pau, Barcelona, Spain

    Alejandro Fernández & Valle Camacho

Authors
  1. Alejandro Fernández
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Valle Camacho
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Alejandro Fernández .

Editor information

Editors and Affiliations

  1. Regional Center of Nuclear Medicine, Department of Translational Research and Advanced Technologies in Medicine and Surgery, University of Pisa, Pisa, Italy

    Duccio Volterrani

  2. Regional Center of Nuclear Medicine, Department of Translational Research and Advanced Technologies in Medicine and Surgery, University of Pisa, Pisa, Italy

    Paola Anna Erba

  3. Hosp. Sant Pau, Nuclear Medicine Department, Autonomous University of Barcelona, Barcelona, Spain

    Ignasi Carrió

  4. Molecular Imaging and Therapy Department, Cornell University Weill, New York, NY, USA

    H. William Strauss

  5. Regional Center of Nuclear Medicine, Department of Translational Research and Advanced Technologies in Medicine and Surgery, University of Pisa, Pisa, Italy

    Giuliano Mariani

Rights and permissions

Reprints and permissions

Copyright information

© 2019 Springer Nature Switzerland AG

About this chapter

Check for updates. Verify currency and authenticity via CrossMark

Cite this chapter

Fernández, A., Camacho, V. (2019). Hybrid Imaging of the Head and Neck Region. In: Volterrani, D., Erba, P.A., Carrió, I., Strauss, H.W., Mariani, G. (eds) Nuclear Medicine Textbook. Springer, Cham. https://doi.org/10.1007/978-3-319-95564-3_19

Download citation

  • DOI: https://doi.org/10.1007/978-3-319-95564-3_19

  • Published:

  • Publisher Name: Springer, Cham

  • Print ISBN: 978-3-319-95563-6

  • Online ISBN: 978-3-319-95564-3

  • eBook Packages: MedicineMedicine (R0)

Publish with us

Policies and ethics

Search

Navigation